CAR T

Regeneron forges CAR-T R&D partnership with bluebird bio

Deal combines Regeneron’s receptor tech with CAR-T biotech’s expertise

Regeneron forges CAR-T R&D partnership with bluebird bio

https://pharmaphorum.com/news/regeneron-forges-car-t-rd-partnership-with-bluebird-bio/

Immuno-Oncology challenges include identifying patients before therapy, limited responses and biomarker research

Challenges facing Immuno-Oncology industry

Immuno-Oncology challenges include identifying patients before therapy, limited responses and biomarker research

https://pharmaphorum.com/partner-content/immuno-oncology-challenges-include-identifying-patients-before-therapy-limited-responses-and-biomarker-research/

Gilead needs deal-maker CEO after Milligan quits

Gilead may be looking for a deal-broker who can kick-start the company’s growth after the lacklustre launch of

Gilead needs deal-maker CEO after Milligan quits

https://pharmaphorum.com/news/gilead-needs-deal-maker-ceo-after-milligan-quits-analyst/

Gilead develops solid tumour cell therapy with Gadeta

Gilead has option to buy biotech if things go well

Gilead develops solid tumour cell therapy with Gadeta

https://pharmaphorum.com/news/gilead-develops-solid-tumour-cell-therapy-with-gadeta/

CAR-Ts – a new weapon in the fight against cancer

CAR-T – or Chimeric Antigen Receptor T-cell therapies herald a new wave of therapies in cancer. CAR-T therapies

CAR-Ts – a new weapon in the fight against cancer

https://pharmaphorum.com/views-and-analysis/car-ts-a-new-weapon-in-the-fight-against-cancer/

CAR-Ts close to EU approval, face further US price scrutiny

Revolutionary CAR-T cell therapies for blood cancer could be on the European market within a few months after

CAR-Ts close to EU approval, face further US price scrutiny

https://pharmaphorum.com/news/car-t-eu-approval-face-further-us-price-scrutiny/

ASCO 2018 – Friday 1st and Saturday 2nd June: Bluebird Bio’s CAR-T shines, plus blood tests for lung cancer

The American Society of Clinical Oncology (ASCO) has already singled out CAR-T therapies as the most promising advance

ASCO 2018 – Friday 1st and Saturday 2nd June: Bluebird Bio’s CAR-T shines, plus blood tests for lung cancer

https://pharmaphorum.com/views-analysis-oncology/asco-round-up-bluebird-bios-car-t-plus-lynch-syndrome-screening/

ASCO 2018 Preview – what to expect from this year’s conference

pharmaphorum will be presenting live online coverage of this year’s ASCO 2018 conference, the biggest event of the

ASCO 2018 Preview – what to expect from this year’s conference

https://pharmaphorum.com/views-and-analysis/asco-2018-preview-conference/

Kite expands manufacturing capacity for CAR-T therapies

Less than a year after it was acquired by Gilead in a $11.9 billion deal, Kite Pharma has

Kite expands manufacturing capacity for CAR-T therapies

https://pharmaphorum.com/news/kite-expands-manufacturing-capacity-for-car-t-therapies/

1 2 3 4 5 >»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Search

Advanced Search

Trending

CAR T